# An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

> **NCT07359066** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai SciBrunch Therapeutics Co., Ltd.** · enrollment: 210 (estimated)

## Conditions studied

- Advanced Solid Tumors
- PARP Inhibitor

## Interventions

- **DRUG:** SRP1020

## Key facts

- **NCT ID:** NCT07359066
- **Lead sponsor:** Shanghai SciBrunch Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-08
- **Primary completion:** 2028-02
- **Final completion:** 2028-06
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07359066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07359066, "An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07359066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*